Moreover, PiHL knockdown reduced HMGA2 levels and restored sensitivity to Oxaliplatin treatment in a CRC xenograft model [137], thus linking HMGA2 tumor levels to Oxaliplatin resistance in CRC. Here, HMGA2 is linked to neoplasm.